trending Market Intelligence /marketintelligence/en/news-insights/trending/BsaXQXXiehVnVs4b-Jh4ag2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Polyphor halts 2 trials of pneumonia drug candidate due to kidney injuries

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Polyphor halts 2 trials of pneumonia drug candidate due to kidney injuries

Polyphor AG temporarily discontinued two late-stage studies of murepavadin in patients with hospital-acquired pneumonia because of incidents of acute kidney injury that were higher than expected.

Acute kidney injury is a sudden episode of kidney failure or damage that can happen within a few hours or a few days.

Switzerland's Polyphor was comparing POL7080, or murepavadin, with antibiotics in two phase 3 studies, Prism-MDR and Prism-UDR. Hospital-acquired pneumonia occurs in patients after admission to a hospital for at least 48 to 72 hours and is usually caused by a bacterial infection, rather than a virus.

Polyphor had expected kidney injury incidences in the range of 25% to 40%. However, it halted the trials after 56% of the patients in the murepavadin arm of the Prism-MDR trial experienced kidney injuries. The company will provide an update on both studies in July after all data is available and reviewed.

Polyphor develops drugs that address antibiotic resistance and enhance therapy outcomes in cancer.